Big Pharma Split Corp.
PRM.TO
TSX
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | 29.16% | -60.22% | -95.38% | -79.01% | -62.14% |
| Total Revenue | 29.16% | -60.22% | -95.38% | -79.01% | -62.14% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 29.16% | -60.22% | -95.38% | -79.01% | -62.14% |
| SG&A Expenses | -10.16% | -14.39% | -19.07% | -17.85% | -15.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 3.32% | -30.21% | -48.72% | -48.61% | -47.85% |
| Total Operating Expenses | -8.27% | -17.33% | -25.67% | -24.47% | -22.10% |
| Operating Income | 44.29% | -69.41% | -106.08% | -87.64% | -68.66% |
| Income Before Tax | 595.82% | -77.43% | -125.62% | -113.81% | -105.99% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 595.82% | -77.43% | -125.62% | -113.81% | -105.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 595.82% | -77.43% | -125.62% | -113.81% | -105.99% |
| EBIT | 44.29% | -69.41% | -106.08% | -87.64% | -68.66% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 525.77% | -66.54% | -131.14% | -117.45% | -108.73% |
| Normalized Basic EPS | 525.79% | -66.54% | -131.13% | -117.45% | -108.73% |
| EPS Diluted | 525.77% | -66.54% | -131.14% | -117.45% | -108.73% |
| Normalized Diluted EPS | 525.79% | -66.54% | -131.13% | -117.45% | -108.73% |
| Average Basic Shares Outstanding | -14.96% | -17.27% | -19.38% | -12.19% | -4.69% |
| Average Diluted Shares Outstanding | -14.96% | -17.27% | -19.38% | -12.19% | -4.69% |
| Dividend Per Share | -1.15% | -1.98% | -3.65% | -5.33% | -5.48% |
| Payout Ratio | 1.17% | 2.58% | -4.03% | -7.10% | -16.46% |
